Effect of Plasminogen Activator Inhibitor-1 4G/5G Polymorphism in Turkish Deep Vein Thrombotic Patients with and without FV1691 G-A

• Published in: Thrombosis research Vol. 97; no. 4; pp. 227 - 230
• Main Authors: Akar, N., Yilmaz, E., Akar, E., Avcu, F., Yalçin, A., Cin, Ş.
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Ltd 15-02-2000; Elsevier Science
• Subjects: Adult; Biological and medical sciences; Blood and lymphatic vessels; Cardiology. Vascular system; Case-Control Studies; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Factor V; Factor V - genetics; Genetic Predisposition to Disease; Humans; Medical sciences; Mutation; Plasminogen Activator Inhibitor 1 - genetics; Plasminogen Activator Inhibitor 1 - metabolism; Plasminogen activator inhibitor-1; Polymorphism, Genetic; Risk Factors; Thrombosis; Turkey; Venous Thrombosis - genetics; Asia; Turkey; Factor V; CI, confidence interval; DVT, deep vein thrombosis; OR, odds ratio; Plasminogen activator inhibitor-1; Thrombosis; PAI-1, plasminogen activator inhibitor-1; Vascular disease; Human; Plasminogen activator inhibitor 1; Pathogenesis; Cardiovascular disease; Deep vein; Genetic determinism; Venous disease; Polymorphism
• ISSN: 0049-3848; 1879-2472
• DOI: 10.1016/S0049-3848(99)00164-4

A decreased fibrinolytic activity due to increased levels of plasminogen activator inhibitor-1 has been shown in deep vein thrombosis patients. Elevated plasma plasminogen activator inhibitor-1 levels are associated with the 4G allele of a 4G/5G polymorphism located in the promoter region of the plasminogen activator inhibitor-1 gene. Because there is no existing data in the Turkish population, we aimed to study these mutations in patients with deep vein thrombosis (
n=136) and normal controls (
n=113), consecutively selected among unrelated healthy subjects without personal and familial history of atherothrombosis from Ankara, Turkey. DNA was extracted by conventional methods, and polymerase chain reaction of the plasminogen activator inhibitor-1 4G/5G polymorphism was performed according to a previously described method. Genotype distributions of FV 1691G-A and plasminogen activator inhibitor-1 4G/5G are as follows: plasminogen activator inhibitor-1 4G (patients) 0.562, plasminogen activator inhibitor-1 4G (controls) 0.50 (
p=0.6); FV1691A (patients) 0.147, FV1691A (controls) 0.035 (
p=0.005). Our data indicated that plasminogen activator inhibitor-1 4G/5G does not have an effect on the thrombotic risk. Carrying the 4G allele either in heterozygous or homozygous state increases the risk in the presence of FV1691A (odds ratio: 9.8 and 6.9, confidence interval 95% 2.9–32.7 and 1.3–35.8). FV1691A is an independent risk factor for thrombosis (odds ratio: 5.5, confidence interval: 95% 2.5–12.1). We concluded that coexistence of FV1691A and plasminogen activator inhibitor-1 4G allele leads to an increased risk for thrombosis leading a further evidence to another prothrombotic factor that may be necessary for the development of a manifest thrombotic event.